Moderna Says Coronavirus Vaccine's Effectiveness Will Likely Hold Against New SARS-CoV-2 Variants

Moderna Inc (NASDAQ: MRNA) has assured that there is nothing to worry as the world is threatened by the prospect of SARS-CoV-2 mutating to produce new virulent strains.
What happened: The vaccine-induced immunity to Moderna's coronavirus vaccine candidate - mRNA-1273 - is likely to protect against the new strain of SARS-CoV-2 recently described in the UK, the Massachusetts-based company said in a Declaration from late Wednesday with.
Scroll to continue with the content
display
Microsoft and Redis
Meet the fast and fully managed in-memory data store.
Don't miss the opportunity to hear the unique perspectives from Microsoft and partner specialists and learn more about Azure Cache for Redis.
LEARN MORE
The company based the deduction on previous data.
Tests of sera from animals and humans vaccinated with mRNA-1273 have been performed against a number of previous variants of SARS-CoV-2, and the vaccine has remained equally effective.
Related Link: Sarepta, Amicus Top Biotech Selects Major Binary Events: Analyst
"The full-length spike protein is 1,273 amino acids long. While newer variants contain several mutations, for example up to 8 amino acid changes in the spike protein of the B1.1.7 strain, these represent less than 1% difference to the spike protein, which is encoded by Moderna's vaccine, "the company stated.
What's next? Moderna plans to run tests to confirm the vaccine's activity against each strain.
The broad spectrum of potential neutralizing antibodies made possible by mRNA-1273 gives confidence that it will also effectively induce neutralizing antibodies against them.
Moderna's vaccine candidate approval from the FDA on December 18, and most recently Health Canada under an interim injunction to vaccinate people aged 18 and over.
See more from Benzinga
Click here for Benzinga option trades
Moderna, Pfizer tests coronavirus vaccine against new strain
The week before biotech: light calendar in an abbreviated week with 1 IPO, 1 FDA decision
© 2020 Benzinga.com. Benzinga does not offer investment advice. All rights reserved.

You should check here to buy the best price guaranteed products.

Last News

Omicron variant case confirmed in Colorado

EJ Williams Opens Up About His First-Ever Onscreen Kiss on 'The Wonder Years' Reboot (Exclusive)

CVS customer catches pharmacy employee's alleged unsanitary behavior on camera: ‘This is the final straw’

The Young and The Restless - Turned It Down

Kayleigh McEnany says she didn't lie in the White House briefing room because she went to Oxford, Harvard, and Georgetown and is a Christian

Multiple cases of omicron virus variant detected in NYC